SCHEMBL4174306

SCHEMBL4174306

Cc1ccc(S(=O)(=O)Oc2ccc(S(=O)(=O)Cc3ccccn3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
RCE1 Q9Y256 1/20 0.47
MAPT P10636 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
PPARG P37231 1/20 0.42
ENPP2 Q13822 1/20 0.41
GAA P10253 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13940197 0.84 ENPP1 (0.47) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL7268263 0.84 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDHSD17B10RCE1
SCHEMBL8237354 0.79 KEAP1 (0.48) ALDH1A1KDM4EHPGDHSD17B10RCE1
SCHEMBL4167643 0.76 KEAP1 (0.45) ALDH1A1KDM4EHPGDHSD17B10RCE1
SCHEMBL9598330 0.76 ALDH1A1 (0.50) ALDH1A1MAPTLMNAPPARGMAPK1
SCHEMBL7695463 0.76 PPARG (0.52) ALDH1A1MAPTLMNASMN1; SMN2PPARG
SCHEMBL28517030 0.76 GAA (0.49) SMN1; SMN2GAAMAPK1TDP1L3MBTL1
SCHEMBL29567873 0.76 GAA (0.49) SMN1; SMN2GAAMAPK1TDP1L3MBTL1
SCHEMBL2070900 0.75 KMT2A (0.57) ALDH1A1KDM4EMAPTLMNASMN1; SMN2
SCHEMBL30595144 0.75 KMT2A (0.57) ALDH1A1KDM4EMAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090017112-A1 Compounds for Inhibiting Beta-Amyloid Production ROSKAMP RESEARCH LLC (US) 2009-01-15 US disclosed
US-20090017112-A1 Compounds for Inhibiting Beta-Amyloid Production ROSKAMP RESEARCH LLC (US) 2009-01-15 US disclosed
US-20090017112-A1 Compounds for Inhibiting Beta-Amyloid Production ROSKAMP RESEARCH LLC (US) 2009-01-15 US disclosed
EP-1993548-A2 COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION Roskamp Research LLC (US) 2008-11-26 EP disclosed
WO-2007103683-A2 COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ROSKAMP RESEARCH LLC (US) 2007-09-13 WO disclosed
WO-2007103683-A2 COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ROSKAMP RESEARCH LLC (US) 2007-09-13 WO disclosed
US-5739340-A Indolizine derivatives with pharmaceutical activity ELF SANOFI (FR) 1998-04-14 US disclosed
US-5403933-A Chemical intermediates for cardiotonic, hypotensive, antiarrhymia and bradycadial agents; cognition activators ELF SANOFI (FR) 1995-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090017112-A1 Compounds for Inhibiting Beta-Amyloid Production PSEN1, PSEN2, APP ALDH1A1 2818/4885KDM4E 4787/4885HPGD 1262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.